Friede est le responsable scientifique des systèmes de distribution de vaccins au sein de l’Initiative pour la recherche sur les vaccins (IVR) à l’Organisation mondiale de la santé à Genève, en Suisse. Dans ce poste, il est le point focal de l’OMS pour les questions liées au développement de technologies visant à améliorer les vaccins, y compris les adjuvants, les méthodes de stabilisation et les systèmes de distribution de vaccins sans aiguille.

Avant de rejoindre l’OMS, le Dr Friede a occupé plusieurs postes dans l’industrie des vaccins : il a été vice-président du développement chez Apovia Inc., une entreprise californienne de développement de vaccins, et, avant cela, il était responsable de la formulation des vaccins et de la recherche sur la distribution des vaccins chez Smithkline Beecham Biologicals (aujourd’hui GlaxoSmithKline). Martin Friede a obtenu son doctorat en biochimie à l’Université de Cape Town en Afrique du Sud.

Danilo is Chief Science Officer and Global Head, External Scientific Affairs for Sanofi Vaccines since October 2021.  He is responsible for external-facing functions of the Vaccines R&D unit, including teams for search-and-evaluation of vaccine candidates and vaccine innovations, scientific network development & partnerships, and external financing.  He has over 25 years of experience in research and development of vaccines and biologics in both pharmaceutical and non-profit sectors.  Prior to joining Sanofi in November 2017, he was the Chief Scientific Officer at Aeras, a non-profit vaccine R&D organization funded by the Bill and Melinda Gates Foundation. During his 19 years at the Merck Research Laboratories, Danilo contributed to the licensure of Merck’s human papillomavirus (HPV) vaccines, and the development of novel vaccine candidates and antibodies against multiple viral pathogens and novel immunotherapeutic approaches against cancer and neurodegenerative diseases.  He also served on numerous advisory committees to the Bill & Melinda Gates Foundation Global Health Program, International AIDS Vaccine Initiative, NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program, USAID Malaria Vaccine Development Program, and HIV Vaccine Enterprise. He received his Ph.D. degree in chemistry and post-doctoral training from the California Institute of Technology and the Scripps Research Institute-La Jolla, respectively.

Research Center, National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (NIH). Chief, Viral Pathogenesis Laboratory and Translational Science Core

Dr. Barney Graham is an immunologist, virologist, and clinical trials physician whose primary interests are viral pathogenesis, immunity, and vaccine development. His work is focused on HIV, respiratory syncytial virus (RSV), and emerging viral diseases. After graduating from Rice University, he obtained his MD from the University of Kansas School of Medicine in 1979. He then completed residency and two chief residencies in Internal Medicine, a fellowship in Infectious Diseases, and a Ph.D. in Microbiology & Immunology at Vanderbilt University School of Medicine, where he rose to the rank of Professor of Medicine with a joint appointment in the Department of Microbiology & Immunology.

Drew Weissman, M.D., Ph.D. is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania. He received his graduate degrees from Boston University School of Medicine. Dr. Weissman, in collaboration with Dr. Katalin Karikó, discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. The nucleoside-modified mRNA-lipid nanoparticle vaccine platform Dr. Weissman’s lab created is used in the first 2 approved COVID-19 vaccines by Pfizer/BioNTech and Moderna. They continue to develop other vaccines that induce potent antibody and T cell responses with mRNA–based vaccines. Dr. Weissman’s lab also develops methods to replace genetically deficient proteins, edit the genome, and specifically target cells and organs with mRNA-LNPs, including lung, heart, brain, CD4+ cells, all T cells, and bone marrow stem cells.

Duccio Medini leads the 60M$ RNA Readiness and Response program, co-funded by CEPI, to develop standardized, multi-product RNA manufacturing capabilities providing increased access to diverse biologics and sustainable pandemic response.

In executive roles of growing responsibility at Chiron, Novartis and GSK corporations, he led hundreds of data scientists in Vaccines R&D across Europe, US and Asia, holding Research Board, Innovation Board, Clinical Quality Board and Data Governance Board responsibilities.

Working across biological discovery, clinical development and public health, he discovered the pangenome concept co-founding the pangenomics discipline, contributed to the successful registration of four novel vaccines, including the first universal vaccine against serogroup B meningitis, led the Meningococcal Antigen Typing System (MATS) platform worldwide, developed transformative corporate data strategies, authored 50+ publications, books and patents in data science for health, population genomics and mathematical vaccinology.

Prof. Medini received his Ph.D. in Physics from the University of Perugia, Italy, with a residency at the Northeastern University in Boston, MA; is habilitated Full Professor of Molecular Biology; has served in international PhD school committees at the Perugia and Turin Universities in Italy; is honorary member of the Cuban Immunology Society, Fellow of the ISI Foundation, Strategic Board member of CINI’s Italian National Digital Health Lab; an IMD, ADVAC and UC Berkley alumnus.

Dr. Connie Schmaljohn is the Director of the NIAID Integrated Research Facility (IRF-Frederick) where she provides overall scientific leadership to research activities and oversees collaborative research programs to advance medical countermeasures for highly pathogenic viruses. In addition, she serves as an expert consultant and advisor both nationally and internationally on the development of novel vaccine strategies for highly pathogenic viruses.

Dr. Schmaljohn earned a BS Degree in Microbiology from the University of Nebraska and a PhD in Virology from Colorado State University, after which she joined United States Army Medical Research Institute of Infectious Diseases (USAMRIID) as a National Research Council postdoctoral fellow.  She continued her career at USAMRIID in multiple capacities culminating with a position as the Senior Research Scientist for Medical Defenses against Infectious Disease Threats for the US Army.  Dr. Schmaljohn’s research background is in molecular virology and molecular vaccine development. She has served as President of the International Society of Hantaviruses, Chair of the American Society for Microbiology Biodefense Conference, and Chair of the International Committee on the Taxonomy of Viruses Bunyaviridae Study Group. She also has served on the Interagency Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Viral Hemorrhagic Fevers IPT, the Board of Scientific Counselors for the NIAID Vaccine Research Center, the Scientific Advisory Council for the Coalition of Emergency Preparedness Innovations (CEPI) and the Independent Product Group (IPG) for COVAX.  She was elected to the American Academy of Microbiology (2007) and was selected as Fellow of the International Society for Vaccines (2015).  She received the Order of Military Merit (2002), the Association of Military Surgeons of the United States Research Award (2002), the University of Nebraska Alumni Achievement Award (2012), and the Presidential Rank Award (2017).  Dr. Schmaljohn has published more than 200 peer reviewed journal articles and reference works, has edited many books and special journal issues and holds numerous patent awards for vaccine development efforts.

Suhaib Siddiqi is a scientist in the field of infectious diseases, nucleic acids and genomics. As a head of the departments, he led the research and development efforts at various biotechnology and pharmaceutical companies.  He was the first director of chemistry at Moderna.

He has a doctorate in Chemistry from the University of Technology, Vienna, Austria. He currently serves as a scientific advisor to various biotechnology companies.  He was inventor of a potent antiviral agent, (-)-5’-Noraristeromycin and Virtual Terminators for the DNA/RNA sequencing.  He has published 31 peer-reviewed papers, and 47 patents.

Kiat Ruxrungtham, MD, is a Professor of Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine, vaccine, immunology, and allergy research and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program. He has published more than 360 peer review papers on HIV, immunology, allergy, and vaccine.